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Introduction
Erectile dysfunction (ED) refers to the inability to achieve 
and/or sustain an erection satisfactory for sexual intercourse. 
An estimated 30–50% of men between the ages of 40–70 years 
of age suffer from moderate or severe ED based on data 
from the United States and Europe (1,2). Treatment begins 
with lifestyle modification followed by medical therapy with 
phosphodiesterase-5 inhibitors (PDE5i). In medication 
refractory patients, or in those with intolerable side effects, 
published guidelines encourage clinicians to discuss 
established treatment such as vacuum erection devices, 
self-administered intracavernosal injection of erectogenic 
agents, intraurethral suppositories, and penile prosthesis 
placement (3).
Over the past several years, there has been considerable 
interest in the concept of “regenerative” therapies for ED 
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treatment. This is logical, as ED results in anatomic and 
functional changes to the erectile tissue characterized by 
progressive cavernosal fibrosis (4). Regenerative treatments 
include injections of stem cells, platelet rich plasma, and 
low-intensity shockwave therapy (LiSWT). There is 
amassing animal data suggesting that these approaches 
may result in angiogenesis and neurogenesis, thereby 
“restoring” dysfunctional erectile tissue (5). To date there 
is limited human data to support regenerative therapies as a 
reliable treatment for ED. Also, the patient characteristics 
associated with treatment success are unclear. This has not 
stopped a barrage of clinics throughout the world from 
offering regenerative therapies for ED, sometimes with 
unsubstantiated claims of benefit, aggressive marketing 
campaigns, and exorbitant out of pocket fees (6). 
Shock wave therapy (SWT) has been widely used for 
many years to treat many conditions. It was first described 
40 years ago for the treatment of renal stones (7) and later 
for bone non-unions (8), chronic wounds (9), ischemic 
heart disease (10) and more recently for sexual dysfunction 
including Peyronie’s Disease and erectile dysfunction 
(ED) (11,12). High-energy SWT (10–20 kV) is used to 
fragmentize urinary tract stones whereas SWT using lower 
energy settings (<0.2 mJ/mm2) has been proposed to treat 
other conditions based on animal model data showing 
potential regenerative properties through angiogenesis and 
neurogenesis (7,8). 
Due to the minimally-invasive nature of this approach, 
SWT is an attractive treatment modality for many 
patients and clinicians. Of the ED regenerative therapies, 
LiSWT has the largest body of literature, including 
several randomized-controlled trials and meta-analyses (9). 
The results are somewhat varied, and there inherent 
challenges in deciphering treatment outcomes due to 
variations in treatment protocols (energy settings, number 
of shocks delivered, duration of therapy, etc.) and patient 
populations. Also, not all shockwave technologies are 
created equal and many of the devices used in commonplace 
are unlikely to exert any effect on erectile tissue (10). 
Given the controversy and lack of clarity surrounding 
LiSWT, as well as the increasing number of clinicians who 
are offering LiSWT within and outside various research 
protocols, herein we sought to provide a comprehensive 
review of LiSWT for the treatment of vasculogenic 
ED with emphasis on mechanism of action, device 
technology, published data, and future considerations (11). 
We present the following article in accordance with the 
Narrative Review Checklist (available at http://dx.doi.
org/10.21037/tau-20-1286).
Mechanism of action
A shockwave refers to an acoustic disturbance with the 
ability to (I) carry energy, and (II) propagate through a 
medium (10,12). The waveform itself is characterized 
by a high peak pressure which is achieved rapidly, and a 
subsequent pressure decay. The wave causes local tissue 
compression followed by expansion related to the tensile 
force of the involved tissue (13). This creates tissue stress 
which is hypothesized to induce neovascularization and 
neuronal regeneration, in part through recruitment and 
activation of local progenitor cells (14,15). 
In normal physiological conditions, vascular endothelial 
cells (EC) are frequently exposed to fluid shear stress created 
by turbulent blood flow. The forces induce cellular changes 
through a process known as “mechanotransduction”, which is 
defined as a (bio)chemical response to mechanical stimuli (16). 
Mechanotransduction modulates EC physiology via 
intracellular and extracellular signaling pathways, mainly 
mediated by vascular endothelial growth factor (VEGF), 
nitric oxide synthase (NOS), and platelet derived growth 
factor (PDGF) leading to angiogenic gene expression in 
ECs (17,18). 
Through effects on local tissue, SWT is hypothesized to 
mimic fluid shear stress, stimulating VEGF and other local 
factor expression to enhance local angiogenesis, particularly 
at low energy settings (19). Hatanaka et al. demonstrated 
in vitro that SWT increased levels of VEGF and endothelial 
nitric oxide synthase (eNOS), and that caveolin-1 and 
ß1-integrin, constitutive proteins of caveolae, which are 
invaginated organelles found in the plasma membrane 
and responsible for cell migration, are integral for SWT-
induced angiogenesis (20). Also, Sokolakis et al. found that 
LiSWT was associated with increased VEGF expression in 
the erectile tissue of naturally aged rats, as well as Liu et al., 
in streptozotocin-induced diabetic rats (21,22). Assaly et al., 
in a study involving rats with hypertension-induced ED, 
showed that LiSWT enhanced angiogenesis in cavernosal 
tissue as shown by CD31 immunohistochemical expression, 
but there was no significant upregulation of NOS (23). The 
authors suggested that, although nitric oxide (NO) presence 
is known to be fundamental for physiological penile 
erection (and the pathway by which PDE5is act), the effect 
of LiSWT may be in part NO-independent and therefore 
beneficial for patients with vasculogenic ED and insufficient 
PDE5i response.
2619Translational Andrology and Urology, Vol 10, No 6 June 2021
  Transl Androl Urol 2021;10(6):2617-2628 | http://dx.doi.org/10.21037/tau-20-1286© Translational Andrology and Urology. All rights reserved.
Mechanical perturbations may also induce neuronal 
regeneration (“neurogenesis”) through local mechanisms (24). 
In a rat model of pelvic neurovascular injuries, Li et al. 
demonstrated, both in vitro and in vivo, that LiSWT 
improved erectile function not only by increasing the 
generation of new blood vessels but also by penile nerve 
regeneration through increased number and proliferation 
of Schwann cells, which are critical for nerve growth and 
regeneration (25). Lin et al. demonstrated that LiSWT also 
has the ability to activate local penile progenitor cells in a rat 
model, suggesting another mechanism for tissue regeneration 
through vascular and neuronal regeneration (26). 
In conclusion, the mechanisms underlying LiSWT 
in the context of erectile tissue regeneration are not 
fully understood but likely involve angiogenesis and 
neurogenesis, namely mediated by growth factor expression 
and nerve regeneration. Local activation and recruitment 
of progenitor cells may also play a role. Thus, from a 
theoretical perspective, this approach, as compared with our 
standard historical treatment approaches, has the potential 
to restore erectile function.
Technical specifications
Shock waves are high-pressure acoustic waves characterized 
by a single rapid and focused pulse followed by a low-tensile 
phase (10,12). These waves are generated by machines 
called lithotripters. There are three types of lithotripters 
in common use: electrohydraulic, electromagnetic and 
piezoelectric (12,27,28). Electrohydraulic waves are 
generated by applying high voltage to electrodes to generate 
a spark. This produces a high-amplitude spherical wave 
which is then focused by a reflector. Electromagnetic waves 
are formed by pulling apart a metal membrane away from an 
electromagnetic coil using a high voltage electric pulse. The 
rapid forward movement of the membrane creates a planar 
acoustic pulse, and the shockwave is focused by an acoustic 
lens or reflector. Piezoelectric technology uses piezoelectric 
crystals that expand rapidly and synchronously when a 
high-voltage electric pulse is applied to them, creating a 
pressure wave. These crystals are distributed in a spherical 
way to focus the energy and do not require a lens or a 
reflector. Contemporary lithotripter machines differ from 
each other regarding specific settings, namely energy flux 
density (EFD), penetration depth, and frequency (Table 1). 
Also, each manufacturer has its own recommended protocol, 
including number and frequency of sessions and number of 
shocks per session (10,12). Differences amongst machine 
technologies/protocols and the absence of head-to-head 
studies make it challenging to determine the superiority of 
one machine and/or protocol over another.
An important consideration that is often overlooked 
by patients and practitioners alike is the concept of linear 
versus radial wave application. This is a distinction that 
merits further clarification. Radial pressure waves are often 
described as “standard” shockwaves, but in essence they act 
Table 1 Contemporary lithotripsy technology used in erectile dysfunction
Omnispec ED 1000 
(Medispec, MD, USA)
Duolith SD1  
(Storz Medical AG,  
Tägerwilen, Switzerland)
Aries 2 (Dornier  
MedTech GmbH, 
Wessling, Germany)
Renova (Direx  
System GmbH,  
Wiesbaden, Germany)
PiezoWave 2  
(Richard Wolf GmbH, 
Knittlingen, Germany)
Technology Electrohydraulic Electromagnetic Electromagnetic Electromagnetic Piezoelectric
Maximal energy 
density (mJ/mm2)
0.23 1.24 0.31 0.09 1.05
Frequency (Hz) 1–3 1–8 1–5 1–5 1–8
Focus penetration 
depth (mm)
0–80 0–125 0–50 0–40 0–40
Advised protocol EFD 0.09 mJ/mm2 EFD 0.15–0.25 mJ/mm2 EFD 0.05 mJ/mm2 EFD 0.09 mJ/mm2 EFD 0.16 mJ/mm2
1,500 shocks/session 3,000 shocks/session 5,000 shocks/session 3,600 shocks/session 4,000 shocks/session
12 sessions (2/week) 
(3 weeks treatment,  
3 weeks no treatment, 
3 weeks treatment)
5 sessions (1/week) or  
12 sessions (2/week)
6 sessions (1 /week) 4 sessions (1/week) 6 sessions (1/week)
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similar to sound waves with a lower peak pressure and rapid 
outward propagation (10,12,29). This results in a much 
shallower depth of penetration. In contrast, linear (focused) 
shockwave devices waves have a distinct focal point and 
a greater depth of penetration. Radial wave generating 
devices are classified as “class 1 medical devices” by the 
United States Food and Drug Administration (FDA) (29). 
This means that “professionals” are not required to have 
additional training prior to offering the therapy to patients 
and there is limited regulatory oversight. In contrast, linear-
wave devices are considered as “class 2 medical devices” 
and require FDA approval to ensure safety and treatment 
efficacy in the United States. Currently, the majority of 
providers in the United States who are offering SWT 
outside of a rigorous research protocol, and especially 
those without urologic and sexual dysfunction expertise, 
are using radial-wave technology (i.e., class 1 medical 
device), whereas the true clinical benefit may lie in the 
application of linear-wave technologies (i.e., class 2 medical 
device) (30). Unfortunately, several of the published study 
protocols that have evaluated LiSWT do not specify the 
type of ultrasound applicator probe which has significant 
implications on the conclusions that can be drawn with 
respect to one technology over another (10).
 
Review of published clinical data
Randomized, sham-controlled clinical trials
Vardi et al. first described LiSWT to treat ED in a 2010 
pilot study involving 20 men with PDE5i-responsive 
erectile dysfunction (31). After a one-month period off all 
oral pharmacotherapy for ED (i.e. washout), participants 
underwent six sessions of penile LiSWT over a nine-week 
period. Follow-up at four-weeks revealed a significant 
increase in International Index of Erectile function-Erectile 
Function Domain (IIEF-EF) scores, from a mean 13.5 (out 
of maximum 30 points), to a mean 20.9, P<0.001). These 
benefits were maintained at three and six-month follow-
up, with an average increase of 7.1 points (P=0.001) (31). 
Improvements in penile hemodynamics were also seen. 
The authors subsequently carried out the first randomized, 
double-blinded, sham-controlled trial with 67 men suffering 
from vasculogenic, PDE5i-responsive ED who were 
randomized to LiSWT versus a sham (placebo) procedure 
using a similar protocol to the original pilot study (32). At 
one-month follow-up, the mean IIEF-EF in the treatment 
group increased by +6.7 points, compared with +3.0 points 
for the sham-therapy arm (P=0.032). Moreover, 65% of men 
in the treatment arm achieved a ≥5-point improvement, 
compared with 20% in the sham arm (P=0.0001). Once 
again, penile hemodynamics were significantly improved in 
the treatment arm. 
Since that time, multiple retrospective, single-arm 
prospective, and randomized-controlled trials have been 
published. This includes 11 randomized, sham-controlled 
trials evaluating the impact of LiSWT on men with 
vasculogenic ED (Table 2) (32-42). Results are somewhat 
mixed owing in part to differences in patient populations, 
study design, outcomes assessed, follow-up duration, and 
the type of shockwave technology utilized. Treatment 
protocols differ in the number of shockwaves delivered with 
each treatment, location of the applied shockwaves, energy 
settings, and the number of treatments administered. 
Also, as discussed above, the type of shockwave transducer 
(i.e., linear versus radial) may impact the likelihood that 
a treatment effect is actually delivered at the level of the 
target tissue. Many of the available LiSWT included in the 
published literature have capabilities for both wave-types 
depending on the transducer (10). Unfortunately, in some 
instances the specific trandsucer used was not delineated, 
thereby adding additional uncertainty with the ability to 
draw definitive conclusions.
I n  t o t a l ,  7 / 1 1  ( 6 4 % )  s h a m - c o n t r o l l e d  t r i a l s 
showed a statistically significant increase in IIEF 
scores in the treatment arm when compared with the 
control arm. IIEF scores (either IIEF-EF or IIEF-
5) in the treatment arm ranged from +1–12.5 points, 
depending on the specific study (32,35,36,38-42). 
3/11 trials (27%) did not show a benefit favoring LiSWT 
over sham (33,34,37). For example, in their study of 
58 patients using a similar shockwave protocol to the 
original trial by Vardi et al., Yee and colleagues did not 
identify any significant difference in outcomes, although 
they did identify a small benefit in subgroup analysis of men 
with “severe ED” (37). Trials from Fojecki et al. and Olsen 
et al. similarly failed to show a significant difference in 
outcomes for LiSWT compared with sham-control (33,34). 
Motil and colleagues did not include a statistical analysis, 
but their results appear to favor LiSWT over sham, with 
>80% of patients in the treatment arm achieving a minimal 
clinically important difference (MCID) in IIEF scores (38). 
This refers to a change in IIEF scores based on the severity 
of underlying ED prior to treatment, as defined by Rosen et 
al. (43).
The majority of randomized trials to date have assessed 
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Table 2 Randomized, sham-controlled trials evaluating outcomes with low-intensity shockwave lithotripsy for vasculogenic erectile dysfunction
Study Info Trial design














# of treatments Objective questionnaire results P value
Vardi  
 et al. (2012)
Randomized, double-blind, 
sham-controlled
40 [20] PDE5i responders Omnispec ED1000 1,500 120/min 0.09 mJ/mm2 15 mins 12 1 month post -Tx: +6.7 (+/-0.9) in IIEF 0.0322
Vascular ED -Sham: 3.0 (+/- 1.4) in IIEF
Olsen  
 et al. (2015)
Randomized, double-blind, 
sham-controlled
51 [54] PDE5i responders Storz Duolith SD1 3,000 NA 0.15 mJ/mm2 NA 5 6 wks post -Tx: 34% w/>5-pt increase in IIEF-EF 0.67





28 [30] Vascular ED Omnispec ED 1000 1,500 120/min 0.09 mJ/mm2 20 mins 12 1 month post -Tx: +5.3 (+/- 5.5) in IIEF vs. Sham: +3.8 (+/- 3.6) in IIEF 0.24
-Post-hoc analysis suggested significant benefit over sham in  
subgroup of men with “severe ED”
Srini  
et al. (2015)
Randomized, controlled,  
double-blind, Sham-controlled
60 [17] PDE5i responders 1,500 120/min 0.09 mJ/mm2 15 mins 12 1-month post for  
comparison between 
sham and tx groups
1-month: -Tx: +12.5 (+/-2.2) in IIEF; -Sham: +1.4 (+/-1.9) in IIEF <0.0001
Vascular ED 12-month post for 
treatment arm





37 [18] Vascular ED Omnispec ED10000 1,500 120/min 0.09 mJ/mm2 15 mins 12 1 month post -Tx: +5 (median; IQR 0–0.95) in IIEF; MCID (40.5%, n=15) 0.0006
PDE5i  
non-responders





58 [60] Vascular ED Wolf PiezoWave/FBL10 1,500 N/A 0.09 mJ/mm2 15 mins 12 12 months post -No significant difference in IIEF after active tx vs. sham (38% tx 
“success” rate in each group)
0.92
Cross-over study PDE5i  
responders






75 [50] Vascular ED Wolf PiezoWave/FBL10 4,000 480 0.16 mJ/mm2 33 mins 4 1-month post -Tx: 81.3% pts (61/75) achieved MCID in IIEF-5 NA
PDE5i  
responders





30 [16] Vascular ED Omnispec ED1000 1,500 160 0.09 mJ/mm2 20 12 3 months post -Tx:56.7% pts achieved MCID in IIEF-EF at 3-mo 0.003
PDE5i  
responders





10 [10] Vascular ED Swiss DolorClast 2,000 200 0.09 mJ/mm2 10 mins 6 3 months post -Tx: + 6.3 in IIEF-5 vs. Sham: + 1.6 in IIEF-5 0.018
Cross-over study Previous renal 
transplant
-IIEF-5 ↑ by >5-pts in 70% of tx group and 10% of Sham group
Vinay  
 et al. (2020)
Randomized, double-blind, 
sham-controlled 
40 [36] Vascular ED Direx Renova  
electromagnetic device
5,000 N/A 0.09 mJ/mm2 N/A 4 1, 3, and  
6 months post
1-month: -Tx: +1 (median; IQR −1, 6) in IIEF;  





3-month: -Tx: +3.5 (median; IQR 0, 10) in IEEF;  
Sham: −0.5 (median; IQR −11, 1) in IIEF
6-month: -Tx: 53% w/EHS >2; Sham: 28% w/EHS >2




38 [43] Mild or moderate  
vascular ED
MT 2000H  
(electromagnetic)
3,000 NA 20 mJ/mm2 (base) NA 12 7 wks post -Tx: mean +5.1 in IIEF (mean EHS: 3.1 +/- 0.6) <0.001
15 mJ/mm2 (shaft)
12 mJ/mm2 (distal penis) -Sham: mean 2.2 pts in IIEF (mean EHS: 2.4 +/- 0.9)
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the effect of LiSWT for vasculogenic ED, but there have 
been at least two randomized, sham-controlled trials that 
evaluated treatment outcomes in men suffering from post-
pelvic surgery ED. Zewin et al. carried out a study involving 
128 men with a history of nerve-sparing cystoprostatectomy 
due to muscle invasive bladder cancer (44). Patients 
were randomized to one of three arms: LiSWT-only, 
PDE5i-only, and no-treatment (control). 76%, 79%, and 
61% of patients recovered “potency” at 9-months after 
cystoprostatectomy, respectively. There was a statistically 
significant difference in IIEF-EF scores amongst all three 
treatment groups relative to baseline (postoperative), 
although there was no significant difference in the degree of 
recovery between the groups. Another study by Baccaglini 
et al. randomized patients to daily PDE5i (tadalafil 
5-mg) starting after catheter removal versus PDE5i plus 
shockwave starting 6-weeks after radical prostatectomy (45). 
The primary clinical end-point for this trial was a four-
point or greater increase in the mean IIEF-5 score favoring 
the treatment arm. The median baseline IIEF-5 scores 
for the treatment and control arm were similar (21 and 
22 points, respectively; P=0.510). The study endpoint was 
defined at 3-weeks after the last LiSWT application or 16 
weeks after prostatectomy. As expected, there was a drop in 
IIEF-5 scores compared with preoperative, but the median 
IIEF-5 was significant greater for the LiSWT arm (12; 
IQR 9.3, 15.8) compared with the control arm (10; IQR 7, 
11; P=0.006). However, this did not meet the pre-specified 
study endpoint criteria and the clinical implications of a 
two-point difference are questionable.
Meta-analyses 
Given the variability seen in published outcomes, several 
groups have attempted to collate the data through meta-
analyses to further delineate any beneficial effects with 
LiSWT on vasculogenic ED (46-53). As is seen in Table 3, 
despite significant differences in study inclusion criteria 
and technology considerations, all of the meta-analyses 
to date have shown a significant increase in IIEF scores 
(i.e., erectile function) for patients treated with LiSWT, 
both from baseline and relative to sham therapy. The 
mean difference (MD) in the IIEF between the treatment 
and sham arms ranged from approximately +2–4 points. 
Moreover, Sokolakis and Hatzichristodoulou found that 
patients treated with shockwave therapy were 8.5 times 
more likely to achieve a MCID in their IIEF score (43,48). 
Who is likely to benefit from LiSWT?
Several analyses also sought to identify patient and 
treatment factors associated with improved outcomes. 
In their systematic review and meta-analysis involving 
14 studies (883 patients), Lu et al. showed that the IIEF of 
patients with mild ED increased significantly after LiSWT 
relative to sham [mean difference (MD) 2.86; 95% CI: 
1.54–4.19; P<0.0001], whereas patients with moderate and 
severe ED did not show a significant increase (49). IIEF 
increased more notably when LiSWT was combined with 
PDE5i use (MD 4.20; 95% CI: 0.16–8.24; P=0.04), supporting 
combination therapy. In contrast, a recent meta-analysis from 
Dong et al. found that patients with moderate and/or severe 
ED experienced greater improvements in their mean IIEF 
scores relative to patients with mild ED (MD: 3.95; 95% CI: 
2.44–5.46; P<0.00001) (53). Regarding technical specifications, 
the number of shocks per session varied between 1,500 to 
5,000, but the biggest improvement was seen with >3,000 (49). 
EFD varied from 0.09 to 0.25 mJ/mm2. In their analysis of 9 
studies (n=637 patients), Man and Li found that lower EFD 
(0.09 vs. 0.1–0.2 mJ/mm2; MD 4.14; 95% CI: 0.87–7.42; 
P=0.01), increased number of shocks (>3,000 per session; 
MD 5.11; 95% CI: 3.18–7.05; P=0.0001) and a shorter total 
treatment course (<6 weeks; MD 3.73; 95% CI: 0.54–6.93; 
P=0.02) were all associated with improved outcomes.(51) It 
is important to emphasize that none of the included studies 
was specifically powered to evaluate these factors. 
Discussion
The treatment paradigm for managing vasculogenic ED 
has remained relatively stagnant for the last two decades. 
In men who are unresponsive or intolerant of oral medications, 
we rely on vacuum erection devices, intracavernosal injections, 
intraurethral suppositories, and the gold-standard penile 
prosthesis. The latest iteration of the American Urological 
Association (AUA) guidelines shifted the discussion, positing 
that a rigid “stepwise” approach, wherein a patient was 
required to try and fail one option before moving on to 
the next, was preventing many patients from receiving the 
treatment needed to optimize their sexual function (3). 
Regenerative therapies have the potential to revolutionize 
our age-old approaches, given the perpetual push to 
develop novel, effective, and less invasive treatments for our 
patients. The underlying mechanisms for these treatments 
are sound-animal models supporting tissue regeneration by 
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Angulo et al. (2017) 12 636 Vascular ED LiSWT resulted in a greater increase in IIEF-EF 
at 1-month relative to baseline, and to a greater 
degree relative to sham (MD 2.78; P<0.001)
N/A
Response relative to sham at 3–6 months unclear
Man and Li (2017) 9 RCTs 637 Vascular ED;  
Peyronie’s  
Disease + ED;  
Pelvic pain + ED
LiSWT significantly increased IIEF (MD 2.54; 
P=0.004) and EHS (Risk difference 0.16; P=0.01)
IIEF scores increased  
significantly for patients 
with mild or severe ED 
(versus moderated ED 
where the increase 
Lower energy density  
(0.09 mJ/mm2), increased 
# of pulses (>3,000), and 
shorter treatment course  
(<6 weeks) resulted in 
greater improvements
Only 1/3rd of studies have 
good blinding and 44% of 
studies had unclear risk of 
bias in randomization
Zou et al. (2017) 4 RCTs 277 Vascular ED “Effective treatment” RR for LiSWT vs. placebo 
was 2.50 (95% CI: 0.74, 8.45) based on IIEF-EF
9-week protocol resulted 
in better results versus 
5-week protocol
“Effective treatment” RR for LiSWT vs. placebo 
was 8.31 (95% CI: 3.88, 17.78) based on EHS
Lu et al. (2016) 7 RCTs 833 Vascular ED;  
Peyronie’s + ED
LiSWT resulted in a greater increase in IIEF-EF 
at 1-month relative to baseline, and to a greater 
degree relative to sham (MD 2.00; 95% CI: 1.19, 
3.53; P<0.001)
On sub-group analysis, 
the difference in IIEF was  
significant at 3-months 
f/u, but not after only 
1-month
LiSWT resulted in a significant greater increase 
in EHS at 1-month (RD 0.47; 95% CI: 0.38, 0.56; 
P<0.00001) and 3-months (RD 0.16; 95% CI: 
0.04, 0.29; P=0.001) after treatment
Patients with “mild” ED 
had a significant increase 
in IIEF, whereas those with 
“moderate” or  
“severe” ED did not
Lower EFD  
(0.09 mJ/mm2), greater 
number of shocks, and 
shorter treatment  
duration resulted in  
greater improvements  
in IIEF
Clavijo et al. (2017) 7 RCTs 602 Vascular ED LiSWT resulted in a 4.17-point (95% CI: −0.5,  
8.3; P<0.0001) difference relative to  
sham-control
No difference seen in 
sub-analysis controlling 
for follow-up, participant 
age, and baseline  
IIEF-EF scores
Table 3 (continued)
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neovascularization and neurogenesis. However, translating 
these findings into human data with evidence of clinically 
meaningful positive outcomes is mandatory prior to upending 
the status quo. 
Data continues to amass with respect to LiSWT as a 
treatment for vasculogenic ED. At least 11 randomized, 
sham-controlled trials have sought to evaluate treatment 
outcomes, with >60% showing a statistically significant 
increase  in  I IEF scores  favor ing  LiSWT (mean 
improvement ranging from 1–12.5 points). Studies in other 
populations such as those with pelvic surgery have shown 
a benefit as well (35,44). To this end, of the at least eight 
available meta-analyses, all have supported a statistically 
significant increase in IIEF-scores with LiSWT (46-53). 
Due to significant heterogeneity in the study protocols, 
what remains unknown is what patient characteristics will 
optimize outcomes with LiSWT. There are some signals 
from the meta-analyses. For example, Lu et al. found that 
patients with mild ED had a significant improvement 
over sham, whereas those with moderate and severe ED 
did not (49). Also, Sokolakis and Hatzichristodoulou 
reported that PDE5i responders were more likely to 
achieve MCID criteria (48). Others such as Clavijo et al. 
reported conflicting results with respect to baseline IIEF-
score and likelihood of response, and there are non-
randomized studies showing that PDE5i non-responders 
may be “salvaged” with LiSWT (50). A recent multi-center, 
prospective, single-arm series from Palmieri et al. found 
that LiSWT, when combined with PDE5i therapy, resulted 
in an average increase in IIEF-EF score of 8.6 points in 
PDE5i “non-responders” (54). 71% achieved a MCID in 
their IIEF-EF scores, and 68% had an EHS ≥3 (i.e., rigidity 
sufficient for penetration). Interestingly, ED symptom 
duration does not appear to influence results based on a 
result study from De Oliveira et al. (55). 
We must also consider treatment protocols which 
include potential variations in energy settings, number of 
applied shocks, and treatment duration. Patel et al. found 
no difference in treatment success in their phase II trial 
comparing a similar number of shocks (3,600) delivered 
over one versus two weeks (56). Kalyvianakis et al. similarly 











IIEF-EF score increased by mean 6.4 points  
(95% CI: 1.78, 11.02) for the LiSWT compared 
with mean 1.65 points (95% CI: 0.92, 2.39; 
P<0.0001)
Greater number of shocks 
associated with greater 
improvement in IIEF score
Campbell et al. 
(2019)
7 RCTs 607 Vascular ED LiSWT resulted in a significantly greater increase 
in IIEF-EF relative to sham (MD 4.13; 95% CI: 
0.80, 7.47; P=0.015)
N/A
Patients who underwent LiSWT were more likely 
to experience an improvement in EHS (RR 6.63; 




10 RCTs 873 Vascular ED LiSWT resulted in a significantly greater increase 
in IIEF-EF relative to sham (MD 3.97; 95% CI: 
2.09, 5.84; P=0.03)
Subgroup analysis of 
PDE5I responders  
revealed a significantly 
greater increase in IIEF-EF 
from baseline and a  
greater proportion of  
patients achieving MCID 
% of patients achieving a MCID in IIEF-EF in the 
LiSWT group was significantly greater relative to 
sham (OR 8.54; 95% CI: 2.64, 27.63; P=0.0003)
Dong et al. (2019) 7 RCTs 522 Vascular ED IIEF scores at 1-month after tx were  
significantly improved relative to baseline in the 
LiSWT treated patients compared with sham  
(MD 1.99 points; 95% CI: 1.35, 2.63; P<0.0001)
N/A
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on the number of sessions administered per week (two 
versus three) and varying energy-flux density (0.05 vs. 
0.1 mJ/mm2) (46). In contrast to this, a meta-analysis found 
that applying a greater number of shocks (at least 3,000) and 
using a lower EFD (0.09 vs. 0.1–0.2 mJ/mm2) may optimize 
outcomes (49). Future work must focus on delineating 
the technical settings that will enhance outcomes for our 
patients if this therapy is to be considered a mainstay. 
A final important caveat when offering a treatment is 
the longevity of positive results. Put another way—do the 
beneficial effects persist after the treatment has ceased? As 
seen in Table 2, the majority of available studies assessed 
short term outcomes at 1–3 months post-treatment. In 
their 2018 study, Kitrey et al. sought to further evaluate the 
persistence of symptom improvement after LiSWT (57). 
The authors followed 156 patients included in several 
different previous study protocols. 99/156 patients (64%) 
were classified as treatment successes at one-month (based 
on achieving a MCID in IIEF-EF). However, by two years 
post-treatment, only 53% (53/99) of these original 
treatment “successes” were able to maintain the beneficial 
effects of LiSWT without maintenance therapy. 0% of 
patient with baseline diabetes mellitus or “severe” ED 
maintained the beneficial effects at two years, as compared 
to 76% in those with “mild” baseline ED and no diabetes. 
This underscores the importance of patient selection and 
pre-treatment counseling to ensure the highest likelihood 
of success. 
There are several national and international organizations 
that have published guideline recommendations surrounding 
LiSWT including the AUA (2018), Asia-Pacific Society 
for Sexual Medicine (APSSM; 2020), European Society of 
Sexual medicine (ESSM; 2019), and European Association 
of Urology (EAU; 2020) (3,58-60). All organizations 
acknowledge LiSWT as a potential treatment for ED with 
promising early clinical studies. The treatment appears 
safe with minimal risk for serious adverse events. The 
majority of adverse events seen in the randomized trials 
were mild and transient, and there have been no dropouts 
reported as a result of treatment adverse effects (58). 
This is true even amongst patients considered higher 
risk such as those on anti-coagulation or anti-platelet 
therapy for cardiovascular disease (61). However, due to 
heterogeneity in the literature surrounding treatment 
protocols and study populations, further investigation 
is necessary before we can label LiSWT as “standard of 
care” outside the scope of clinical research. Accordingly, 
LiSWT is recommended by the EAU as a first-line 
treatment alternative in patients with vasculogenic ED 
who are uninterested or unable to tolerate oral therapy 
and who are poor PDE5i responders, but this is based on 
weak evidence (60). The APSSM similarly suggests that 
LiSWT be offered to men with mild/moderate vasculogenic 
ED who do or do not respond to PDE5i (level 2 ; 
grade b) (58). The AUA and ESSM, in contrast, consider 
LiSWT as deserving of more investigation or experimental, 
respectively (3,59). 
Conclusions
Vasculogenic ED is common, and regenerative therapies 
have the potential to transform our historical treatment 
paradigms. LiSWT is one such approach that, based 
on promising animal model data, encourages tissue 
regeneration through various mechanism including 
angiogenesis, neurogenesis, and progenitor cell recruitment. 
Several early single-arm studies and multiple randomized, 
sham-controlled trials support a possible therapeutic 
benefit for men with vasculogenic ED. Based on the 
currently available data, LiSWT appears most likely to 
benefit patients with mild/moderate ED and few medical 
comorbidities. LiSWT may optimize response to PDE5i or 
enhance medication response in PDE5i “non-responders”. 
Linear ultrasound probes (as opposed to radial) should 
be considered standard of care. They are the only probes 
that have been consistently shown to benefit patients 
based on the available literature, although in practice 
radial shockwave probes are commonplace. Future work 
is needed to investigate device technologies, therapeutic 
administrative protocols (number of shocks, treatment 
duration), and patient characteristics associated with 
optimal treatment outcomes. In the meantime, appropriate 
pre-treatment expectations must be discussed at the outset. 
Patients should be adequately counseled regarding what 
is known and unknown about LiSWT, particularly as it 
pertains to treatment protocols and study populations 
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